CN111278861A - Pd-l1抗体、其抗原结合片段及医药用途 - Google Patents

Pd-l1抗体、其抗原结合片段及医药用途 Download PDF

Info

Publication number
CN111278861A
CN111278861A CN201980005432.2A CN201980005432A CN111278861A CN 111278861 A CN111278861 A CN 111278861A CN 201980005432 A CN201980005432 A CN 201980005432A CN 111278861 A CN111278861 A CN 111278861A
Authority
CN
China
Prior art keywords
seq
cancer
chain variable
amino acid
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980005432.2A
Other languages
English (en)
Other versions
CN111278861B (zh
Inventor
顾晓玲
蒋家骅
张蕾
胡齐悦
顾津明
陶维康
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Publication of CN111278861A publication Critical patent/CN111278861A/zh
Application granted granted Critical
Publication of CN111278861B publication Critical patent/CN111278861B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

一种新的PD‑L1抗体、其抗原结合片段及医药用途。包含所述PD‑L1抗体CDR区的人源化抗体，以及包含PD‑L1抗体及其抗原结合片段的药物组合物，以及其作为药物的用途。一种人源化的PD‑L1抗体在制备用于治疗PD‑L1相关的疾病或病症的药物中的用途。

Description

PCT国内申请，说明书已公开。

Claims (18)

  1. PCT国内申请，权利要求书已公开。
CN201980005432.2A 2018-01-10 2019-01-09 Pd-l1抗体、其抗原结合片段及医药用途 Active CN111278861B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810023267 2018-01-10
CN2018100232670 2018-01-10
PCT/CN2019/070982 WO2019137397A1 (zh) 2018-01-10 2019-01-09 Pd-l1抗体、其抗原结合片段及医药用途

Publications (2)

Publication Number Publication Date
CN111278861A true CN111278861A (zh) 2020-06-12
CN111278861B CN111278861B (zh) 2022-05-27

Family

ID=67219311

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980005432.2A Active CN111278861B (zh) 2018-01-10 2019-01-09 Pd-l1抗体、其抗原结合片段及医药用途

Country Status (12)

Country Link
US (1) US11359021B2 (zh)
EP (1) EP3741777A4 (zh)
JP (1) JP2021510078A (zh)
KR (1) KR20200108306A (zh)
CN (1) CN111278861B (zh)
AU (1) AU2019206958A1 (zh)
BR (1) BR112020013475A2 (zh)
CA (1) CA3087105A1 (zh)
MX (1) MX2020007406A (zh)
TW (1) TWI717678B (zh)
WO (1) WO2019137397A1 (zh)
ZA (1) ZA202004907B (zh)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110760517A (zh) * 2019-10-09 2020-02-07 天津大学 拮抗pd-1骆驼抗体类似物ap基因及蛋白和应用
WO2023046113A1 (zh) * 2021-09-24 2023-03-30 广东菲鹏制药股份有限公司 一种抗人pd-l1人源化抗体或其抗原结合片段及其应用
CN115925937A (zh) * 2022-08-05 2023-04-07 赛灵药业科技集团股份有限公司北京分公司 一种抗体或其片段及其制药用途

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6983371B2 (ja) * 2015-11-17 2021-12-17 スーヂョウ サンケイディア バイオファーマスーティカルズ カンパニー リミテッド 抗ｐｄ−ｌ１抗体、その抗原結合フラグメントおよびその医療用途
WO2022121846A1 (zh) * 2020-12-08 2022-06-16 博际生物医药科技(杭州)有限公司 Pd-l1抗体及其应用
TWI789679B (zh) * 2021-01-12 2023-01-11 大陸商江蘇先聲藥業有限公司 抗人程序性死亡配體-1（pd-l1）的抗體及其用途
CN115521378B (zh) * 2021-07-23 2023-12-22 南京吉盛澳玛生物医药有限公司 Pd-l1抗体及其用途
CN115785269B (zh) * 2022-11-01 2023-09-22 四川大学 抗pd-l1的抗体及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110271358A1 (en) * 2008-09-26 2011-11-03 Dana-Farber Cancer Institute, Inc. Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
WO2017084495A1 (zh) * 2015-11-17 2017-05-26 江苏恒瑞医药股份有限公司 Pd-l1抗体、其抗原结合片段及其医药用途
US20170204184A1 (en) * 2014-08-05 2017-07-20 Cb Therapeutics, Inc. Anti-pd-l1 antibodies
CN107216389A (zh) * 2016-03-18 2017-09-29 苏州纳洛迈生物科技有限公司 抗pd-l1纳米抗体及其编码序列和用途
CN107365383A (zh) * 2017-07-12 2017-11-21 苏州大学附属第医院 一种人源化抗人pd‑1单克隆抗体及其制备方法、用途与药物

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
CA3016482A1 (en) 1999-11-30 2001-06-07 Mayo Foundation For Medical Education And Research B7-h1, a novel immunoregulatory molecule
US6803192B1 (en) 1999-11-30 2004-10-12 Mayo Foundation For Medical Education And Research B7-H1, a novel immunoregulatory molecule
CN104356236B (zh) * 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
CN101104640A (zh) 2006-07-10 2008-01-16 苏州大学 抗人pd-l1单克隆抗体制备及应用
KR101050829B1 (ko) * 2008-10-02 2011-07-20 서울대학교산학협력단 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제
PE20120341A1 (es) * 2008-12-09 2012-04-24 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t
WO2010089411A2 (en) 2009-02-09 2010-08-12 Universite De La Mediterranee Pd-1 antibodies and pd-l1 antibodies and uses thereof
KR101573109B1 (ko) * 2009-11-24 2015-12-01 메디뮨 리미티드 Ｂ７―ｈ１에 대한 표적화된 결합 물질
LT2785375T (lt) 2011-11-28 2020-11-10 Merck Patent Gmbh Anti-pd-l1 antikūnai ir jų panaudojimas
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
CN115093480A (zh) 2012-05-31 2022-09-23 索伦托药业有限公司 与pd-l1结合的抗原结合蛋白
ES2848052T3 (es) 2012-08-03 2021-08-05 Dana Farber Cancer Inst Inc Anticuerpos de unión dual anti-PD-L1 y PD-L2 de agente individual y métodos de uso
WO2014055897A2 (en) 2012-10-04 2014-04-10 Dana-Farber Cancer Institute, Inc. Human monoclonal anti-pd-l1 antibodies and methods of use
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
RU2701378C2 (ru) 2013-03-15 2019-09-26 Дженентек, Инк. Биомаркеры и способы лечения связанных с pd-1 и pd-l1 состояний
EP3003282A1 (en) 2013-06-03 2016-04-13 Novartis AG Combinations of an anti-pd-l1 antibody and a mek inhibitor and/or a braf inhibitor
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
MY175472A (en) 2013-09-27 2020-06-29 Genentech Inc Anti-pdl1 antibody formulations
CN105777906B (zh) 2014-12-19 2019-04-23 苏州丁孚靶点生物技术有限公司 抗pd-l1全人抗体及其应用
CA2978942A1 (en) * 2015-03-13 2016-09-22 Cytomx Therapeutics, Inc. Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
CN106243225B (zh) * 2015-06-11 2021-01-19 智翔（上海）医药科技有限公司 新型抗-pd-l1抗体
EP3455257B1 (en) 2016-05-09 2021-09-22 IGM Biosciences Inc. Anti-pd-l1 antibodies
CN106699891B (zh) * 2017-01-25 2019-04-09 北京天广实生物技术股份有限公司 一种抗pd-l1抗体、其药物组合物及其用途
WO2019129136A1 (zh) * 2017-12-27 2019-07-04 信达生物制药(苏州)有限公司 抗pd-l1抗体及其用途

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110271358A1 (en) * 2008-09-26 2011-11-03 Dana-Farber Cancer Institute, Inc. Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
US20170204184A1 (en) * 2014-08-05 2017-07-20 Cb Therapeutics, Inc. Anti-pd-l1 antibodies
WO2017084495A1 (zh) * 2015-11-17 2017-05-26 江苏恒瑞医药股份有限公司 Pd-l1抗体、其抗原结合片段及其医药用途
CN107216389A (zh) * 2016-03-18 2017-09-29 苏州纳洛迈生物科技有限公司 抗pd-l1纳米抗体及其编码序列和用途
CN107365383A (zh) * 2017-07-12 2017-11-21 苏州大学附属第医院 一种人源化抗人pd‑1单克隆抗体及其制备方法、用途与药物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JULIE R. BRAHMER等: "Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer", 《N ENGL J MED》 *
魏木兰等: "PD-1/PD-L1抗体在肿瘤临床治疗中的应用", 《生命科学》 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110760517A (zh) * 2019-10-09 2020-02-07 天津大学 拮抗pd-1骆驼抗体类似物ap基因及蛋白和应用
CN110760517B (zh) * 2019-10-09 2022-04-29 天津大学 拮抗pd-1骆驼抗体类似物ap基因及蛋白和应用
WO2023046113A1 (zh) * 2021-09-24 2023-03-30 广东菲鹏制药股份有限公司 一种抗人pd-l1人源化抗体或其抗原结合片段及其应用
CN115925937A (zh) * 2022-08-05 2023-04-07 赛灵药业科技集团股份有限公司北京分公司 一种抗体或其片段及其制药用途
CN116789833A (zh) * 2022-08-05 2023-09-22 赛灵药业科技集团股份有限公司北京分公司 一种抗体或其片段及其制药用途
CN116789833B (zh) * 2022-08-05 2023-12-12 赛灵药业科技集团股份有限公司北京分公司 一种抗体或其片段及其制药用途

Also Published As

Publication number Publication date
US11359021B2 (en) 2022-06-14
WO2019137397A1 (zh) 2019-07-18
RU2020124261A (ru) 2022-01-25
RU2020124261A3 (zh) 2022-01-25
KR20200108306A (ko) 2020-09-17
BR112020013475A2 (pt) 2020-12-08
ZA202004907B (en) 2022-10-26
MX2020007406A (es) 2020-09-14
US20200339692A1 (en) 2020-10-29
EP3741777A4 (en) 2021-10-13
TWI717678B (zh) 2021-02-01
TW201930360A (zh) 2019-08-01
JP2021510078A (ja) 2021-04-15
CA3087105A1 (en) 2019-07-18
EP3741777A1 (en) 2020-11-25
CN111278861B (zh) 2022-05-27
AU2019206958A1 (en) 2020-07-16

Similar Documents

Publication Publication Date Title
US11365255B2 (en) PD-1 antibody, antigen-binding fragment thereof, and medical application thereof
JP7317272B2 (ja) Ｔｉｇｉｔ抗体、その抗原結合断片及びその医療用途 本願は、２０１９年９月２９日に出願された出願番号ｃｎ２０１７１０９０８５６５．３に基づいたものであり、その優先権を主張する。その開示は、その全体が参照により本明細書に組み込まれる。
TWI796328B (zh) Ｂ７-ｈ３抗體、其抗原結合片段及其醫藥用途
US11359021B2 (en) PD-L1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
TWI758558B (zh) Cd96抗體、其抗原結合片段及醫藥用途
TW202017945A (zh) 抗ｃｄ７３抗體、其抗原結合片段及應用
CN110790839B (zh) 抗pd-1抗体、其抗原结合片段及医药用途
US20210363266A1 (en) Anti-4-1bb antibody, antigen-binding fragment thereof and medical use thereof
CN112969716A (zh) 抗pd-1抗体、其抗原结合片段及医药用途
CN111744013A (zh) 抗tigit抗体联合pd-1抑制剂治疗疾病的方法和药物组合
JP2020508658A (ja) Ｔｉｍ−３抗体、その抗原結合断片、及びそれらの医学的使用
WO2021098822A1 (zh) 一种双特异性抗体
CN112513088B (zh) 抗ox40抗体、其抗原结合片段及其医药用途
KR20240063177A (ko) B7-h3 항체, 이의 항원-결합 단편 및 이의 의학적 용도

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40032196

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant